TATA-box binding protein associated factor, RNA polymerase I subunit CGenealiases: MGC:39976 · SL1 · TAFI110 · TAFI95
Q-omics provides the consensus-scored TAF1C profile across patient tissues and cancer cell-line models. TAF1C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAF1C is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TAF1C protein abundance shows 26,126 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TAF1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1C survival associations across molecular data types. TAF1C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1C RNA expression–survival associations across cancer types. High TAF1C expression shows unfavorable associations in KIRC, ACC and COAD, but favorable associations in SCLC, PAAD and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAF1C RNA expression.
This table summarizes TAF1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TAF1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1C shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, LIHC and STAD. The HNSC box plot shows higher TAF1C RNA expression in tumor versus normal tissue (log2 FC = +0.783, t-test p < 0.001).
This table shows molecular features associated with TAF1C in patient tissues and cancer cell lines. In patient samples, TAF1C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
